Astralis Registration Statement Declared Effective by the SEC FAIRFIELD, N.J., July 6 /PRNewswire-FirstCall/ -- Astralis Ltd. (OTC:ASTR) (BULLETIN BOARD: ASTR) today announced that the Securities and Exchange Commission has declared effective its Registration Statement on Form SB-2 covering 47,056,520 shares of common stock (of which 11,446,654 are issuable upon exercise of warrants) for the resale of such shares from time to time by selling stockholders. The Company will not receive any proceeds from the resales of shares by the selling stockholders. However, if the warrants are exercised for cash, the Company would receive the exercise proceeds. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Notes to the Editor Astralis Ltd., a biotechnology company based in New Jersey, focuses on the research and development of novel treatments for immune system disorders and skin diseases. Psoraxine(R), administered by intramuscular injection, is a protein-based therapy that is believed to stimulate cells from the patient's immune system to reverse the inflammatory process responsible for psoriasis symptoms. Psoraxine(R) is currently being tested in U.S. Phase II clinical trials. For more information, visit Astralis' web site at http://www.astralisltd.com/. Astralis Ltd 75 Passaic Ave Fairfield, New Jersey, 07004 Fax: 1 (973) 227- 7169 Phone: 1 (973) 227- 7168 Email: Mike Ajnsztajn, Chief Executive Officer Gina Tedesco, Chief Financial Officer This news release contains forward-looking statements based on information available to Astralis as of the date hereof. Astralis' actual results could differ materially from the results stated or implied by such forward-looking statements due to a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, general economic and business conditions, changes in governmental laws and regulations relating to the development and commercialization of pharmaceutical products, and competition in our industry. There can be no assurance that our product development efforts will succeed, that Psoraxine(R) will receive required regulatory clearance or that, even if such regulatory clearance were received, that Psoraxine will ultimately achieve commercial success. Astralis disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. DATASOURCE: Astralis Ltd. CONTACT: Mike Ajnsztajn, Chief Executive Officer, or Gina Tedesco, Chief Financial Officer, +1-973-227-7168, or fax, +1-973-227-7169, Web site: http://www.astralisltd.com/

Copyright